PriceTargets.com logo

Electra Therapeutics - ETRA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$9.35 As of 10/13/2026 09:15 AM ET
▲ +0.03 (0.32%)

This chart shows the closing price for ETRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Electra Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ETRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ETRA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Electra Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.35.

This chart shows the closing price for ETRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Electra Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/16/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/16/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/15/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/13/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/13/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/13/2026Jefferies Financial GroupInitiated CoverageBuy$32.00
10/13/2026Cantor FitzgeraldInitiated CoverageOverweight
10/13/2026EvercoreInitiated CoverageOutperform$36.00
10/13/2026TD CowenInitiated CoverageBuy
(Data available from 10/13/2021 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/17/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/16/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/15/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/15/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/14/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/13/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/13/2026

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Electra Therapeutics

Electra Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company's lead product candidate includes ipsoprubart. Electra Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.
Read More

Today's Range

Now: $9.35
Low: $9.35
High: $9.35

50 Day Range

MA: N/A

52 Week Range

Now: $9.35
Low: $8.63
High: $15.50

Volume

2,091 shs

Average Volume

570,276 shs

Market Capitalization

$586.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Electra Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Electra Therapeutics in the last year: Cantor Fitzgerald, Evercore Inc, Jefferies Financial Group Inc., TD Cowen, and Wall Street Zen.
View the latest analyst ratings for ETRA.

What is the current price target for Electra Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Electra Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Electra Therapeutics in the next year.
View the latest price targets for ETRA.

What is the current consensus analyst rating for Electra Therapeutics?

Electra Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ETRA will outperform the market and that investors should add to their positions of Electra Therapeutics.
View the latest ratings for ETRA.

How do I contact Electra Therapeutics' investor relations team?

Electra Therapeutics' physical mailing address is 230 EAST GRAND AVENUE, SUITE S-100, SOUTH SAN FRANCISCO, California, 94080. The company's listed phone number is 888-743-2290 and its investor relations email address is [email protected]. The official website for Electra Therapeutics is www.electra-therapeutics.com. Learn More about contacing Electra Therapeutics investor relations.